ArticleNature communications2025
Anti-Ebola virus mAb 3A6 protects highly viremic animals from fatal outcome via binding GP
Abstract read
In one paragraph
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
26 authors.
Kathryn M HastieCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-3406-1210
Zhe Li Salie *Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-2063-1013
Zunlong Ke *Division of Structural Studies, Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.
Peter J HalfmannInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI, USA.ORCID http://orcid.org/0000-0002-1648-1625
Lisa Evans DeWaldIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD, USA.
Sara McArdleMicroscopy Core, La Jolla Institute for Immunology, La Jolla, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-3795-3772
Ariadna GrinyóIntegral Molecular, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-0185-2734
Edgar DavidsonIntegral Molecular, Philadelphia, PA, USA.
Sharon L SchendelCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-5062-7261
Chitra HariharanCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Michael J NorrisCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-8325-5257
Xiaoying YuCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-6778-5004
Chakravarthy ChennareddyDepartment of Microbiology and Immunology, Emory Vaccine Center, Atlanta, GA, USA.
Xiaoli XiongDivision of Structural Studies, Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.ORCID http://orcid.org/0000-0002-4632-9122
Megan HeinrichZalgen Labs LLC, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-3079-6500
Michael R HolbrookIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD, USA.ORCID http://orcid.org/0000-0002-0824-2667
Benjamin DoranzIntegral Molecular, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-8245-3083
Ian CrozierClinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID http://orcid.org/0000-0003-2485-4011
Yoshihiro KawaokaInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI, USA.ORCID http://orcid.org/0000-0001-5061-8296
Luis M BrancoZalgen Labs LLC, Frederick, MD, USA.
Jens H KuhnIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD, USA. kuhnjens@niaid.nih.gov.ORCID http://orcid.org/0000-0002-7800-6045
John A G BriggsDivision of Structural Studies, Medical Research Council Laboratory of Molecular Biology, Cambridge, UK. briggs@biochem.mpg.de.ORCID http://orcid.org/0000-0003-3990-6910
Gabriella WorwaIntegrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD, USA. gabriella.worwa@nih.gov.
Carl W DavisDepartment of Microbiology and Immunology, Emory Vaccine Center, Atlanta, GA, USA. cwdavi2@emory.edus.
Rafi AhmedDepartment of Microbiology and Immunology, Emory Vaccine Center, Atlanta, GA, USA. rahmed@emory.edu.ORCID http://orcid.org/0000-0002-9591-2621
Erica Ollmann SaphireCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA. erica@lji.org.ORCID http://orcid.org/0000-0002-1206-7451
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MSpecific and Broadly Active Monoclonal Antibody Therapeutics Against The FilovirusesU19AI142790 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SAPHIRE, ERICA OLLMANN · 2019 to 2023
$40.0MX-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6MHigh-Speed High-Sensitivity Detector for X-ray Micro-Crystallography at GM/CA@APSS10OD012289 · OD · UNIVERSITY OF CHICAGO · PI FISCHETTI, ROBERT F. · 2014 to 2014
$2.0MNCI NIH HHS 75N91019D00024NCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INIAID NIH HHS HHSN272200700016INIAID NIH HHS HHSN272201400058CNIAID NIH HHS HHSN272201800013CNIAID NIH HHS U19 AI142790NIGMS NIH HHS P41 GM103393NIH HHS S10 OD012289RCUK | Medical Research Council (MRC) MC_UP_1201/16United States Department of Defense | Defense Advanced Research Projects Agency (DARPA) W31P4Q-14-1-0010
Abstract
Monoclonal antibodies (mAbs) against Ebola virus (EBOV) glycoprotein (GP
Indexed as
Antibodies, MonoclonalAntibodies, ViralEbolavirusHemorrhagic Fever, EbolaViral Envelope ProteinsViremiaVirionAnimalsAntibodies, NeutralizingCryoelectron MicroscopyCrystallography, X-RayDisease Models, AnimalEpitopesFemaleGuinea PigsHumansAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralEpitopesViral Envelope Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.